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2Abstract
Previously, we reported the involvement of brain -6 prostanoids, especially 
prostaglandin E2 and thromboxane A2, in the activation of central sympatho-
adrenomedullary outflow in rats. -3 Prostanoids, including prostaglandin E3 and
thromboxane A3, are believed to be less bioactive than -6 prostanoids, although 
studies on the functions of -3 prostanoids in the central nervous system have not been 
reported. In the present study, therefore, we compared the effects of centrally 
administered -3 prostanoids, prostaglandin E3 and thromboxane A3, with those of -6 
prostanoids, prostaglandin E2 and thromboxane A2, on the plasma catecholamines in 
anesthetized rats. Intracerebroventricularly (i.c.v.) administered prostaglandin E2 (0.15, 
0.3 and 1.5 nmol/animal) and prostaglandin E3 (0.3 and 3 nmol/animal) predominantly
elevated plasma noradrenaline but not adrenaline, but the latter was less efficient than
the former. On the other hand, U-46619 (an analog of thromboxane A2) (30, 100 and 
300 nmol/animal, i.c.v.) and ∆17-U-46619 (an analog of thromboxane A3) (100 and 300 
nmol/animal, i.c.v.) both elevated plasma catecholamines (adrenaline >>
noradrenaline) to the same degree. These results suggest that centrally administered 
prostaglandin E3 is less effective than prostaglandin E2 to elevate plasma noradrenaline,
and that thromboxane A3 is almost as equipotent as thromboxane A2 to elevate plasma
catecholamines in rats.
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41.  Introduction
Prostanoids (prostaglandins and thromboxanes) are bioactive lipids derived from 
membrane polyunsaturated fatty acid (PUFA). Cyclooxygenase is the key enzyme in 
prostanoids synthesis from arachidonic acid, a common -6 PUFA. On the other hand, 
-3 PUFA (eicosapentaenoic acid and docosahexaenoic acid) found primarily in fish 
oils can function as substrates for cyclooxygenase (Jump, 2002). When the availability 
of -3 PUFA is increased by fish oil ingestion, the formation of -3 PUFA-derived 
prostanoids (-3 prostanoids) such as prostaglandin E3 is increased but the 
corresponding -6 PUFA-derived prostanoids (-6 prostanoids) such as prostaglandin 
E2 is reduced (Fischer and Weber, 1984; Fischer et al., 1988; Knapp, 1990). Although 
similar in structure and stability (Hansen, 1983), -3 prostanoids have been considered 
to be less bioactive than -6 prostanoids. For instance, prostaglandin E3, unlike 
prostaglandin E2, is not mitogenic to NIH 3T3 fibroblasts and substantially less 
efficient than prostaglandin E2 in interleukin-6 synthesis in RAW 264.7 macrophages
(Bagga et al., 2003). Prostaglandin F3alpha is less protective than prostaglandin F2alpha
against gastric mucosal injury in rats (Faust et al., 1989) and prostaglandin I3 is less 
potent than prostaglandin I2 in inhibition of platelet aggregation in rabbits (Kobzar et 
al., 2001). However, studies directly comparing the functions of -6 versus -3 
prostanoids in the central nervous system have not been reported, although -3 PUFA
deficiency has been shown to be associated with memory loss and diminished 
cognitive function (Salem et al., 2001).
5It has been demonstrated that -6 prostanoids act as a neurotransmitter and/or 
neuromodulator in the brain’s actions on the cardiovascular function (Wood et al., 
1993; Zhang et al., 2003) and regulation of hormone secretion (Bernardini et al., 1989; 
Reimsnider and Wood, 2006). We previously reported that centrally administered 
arachidonic acid, a source of -6 prostanoids, elevated plasma levels of noradrenaline 
and adrenaline by a cyclooxygenase-dependent mechanism in rats (Yokotani et al., 
2000). Furthermore, centrally administered -6 prostanoid prostaglandin E2 (but not 
prostaglandin D2, I2 and F2alpha) elevated plasma noradrenaline in rats (Yokotani et al., 
1995, 2005; Murakami et al., 2002) and thromboxane A2 mimetic elevated plasma 
catecholamines (adrenaline >> noradrenaline) in rats (Murakami et al., 2002). These 
lines of evidence suggest that centrally administered -6 prostanoids, especially 
prostaglandin E2 and thromboxane A2, activate the central sympatho-adrenomedullary 
outflow in rats. In the present study, therefore, we compared the effects of centrally 
administered -3 prostanoids (prostaglandin E3 and thromboxane A3) and -6
prostanoids (prostaglandin E2 and thromboxane A2) on the plasma catecholamines 
using urethane-anesthetized rats.
62.  Materials and methods
   
2.1.  Experimental procedures
Male Wistar rats weighing about 350 g were maintained in an air-conditioned 
room at 22-24°C under a constant day-night rhythm for more than 2 weeks and given 
food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. 
Under urethane anesthesia (1.2 g/kg, i.p.), the femoral vein was cannulated for infusion 
of saline (1.2 ml/h) and the femoral artery was cannulated for collecting blood samples. 
After these procedures, the animal was placed in a stereotaxic apparatus, as shown in 
our previous papers (Yokotani et al., 1995; Shimizu et al., 2004). The skull was drilled 
for intracerebroventricular administration of test substances using a stainless-steel 
cannula (0.3 mm outer diameter). The stereotaxic coordinates of the tip of the cannula 
were as follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, 
lateral from the midline; V, below the surface of the brain), according to the rat brain 
atlas (Paxinos and Watson, 1986). Three hours were allowed to elapse before the 
application of reagents.
Prostaglandin E2 and prostaglandin E3 were dissolved in 99% ethanol and stored 
at –20°C. These stock solutions were diluted with saline whenever we used them and 
the final concentration of ethanol was adjusted to 0.5%. These diluted solutions were 
slowly injected into the right lateral ventricle in a volume of 10 µl/animal using a 25-µl 
Hamilton syringe. U-46619 and ∆17-U-46619 dissolved in 100% N,N-
dimethylformamide (DMF) were intracerebroventricularly (i.c.v.) administered in a 
7volume of 2.5 µl/animal using a 10-µl Hamilton syringe. Each animal received only 
one dose of these reagents or vehicles.
All experiments were conducted in compliance with the guiding principles for 
the care and use of laboratory animals approved by Kochi University.
  
2.2.  Measurement of plasma catecholamines
Blood samples (250 µl) were collected through an arterial catheter and were 
preserved on ice during experiments. Plasma was prepared immediately after the final 
sampling. Catecholamines in the plasma were extracted by the method of Anton and 
Sayre (1962) with a slight modification and were assayed electrochemically with high 
performance liquid chromatography (HPLC) (Shimizu et al., 2004). Briefly, after 
centrifugation (1,500 g for 10 min, at 4°C), the plasma (100 µl) was transferred to a 
centrifuge tube containing 30 mg of activated alumina, 2 ml of twice deionized water, 
1 ml of 1.5 M Tris Buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-
dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the 
alumina was washed three times with 4 ml of ice-cold twice deionized water. Then, 
catecholamines adsorbed onto the alumina were eluted with 300 µl of 4% acetic acid 
containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, Kyoto, Japan), a 
sample injector (Model-231XL; Gilson, Villiers-le-Bel, France) and an electrochemical 
detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC. 
Analytical conditions were as follows: detector, +450 mV potential against an
Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); 
8mobile phase, 0.1 M NaH2PO4-Na2HPO4 buffer (pH 6.0) containing 50 mg/l disodium
EDTA, 0.75 g/l sodium 1-octanesulfonate and 15% methanol at a flow of 0.18 ml/min; 
injection volume, 40 µl. The amount of catecholamines in each sample was calculated 
using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, 
coefficients of variation for intra- and inter-assay were 3.0 and 3.7%, respectively, and 
0.5 pg of noradrenaline and adrenaline was accurately determined.
2.3.  Treatment of data and statistics 
All values are expressed as the means±S.E.M. of the net changes above the 
respective basal values. The data were analyzed by repeated-measure analysis of 
variance (ANOVA), followed by post-hoc analysis with the Bonferroni method. P
values less than 0.05 were taken to indicate statistical significance.
2.4.  Compounds
The following drugs were used: prostaglandin E2 (Sigma Aldrich Fine Chemicals, 
St. Louis, MO, U.S.A.); prostaglandin E3, U-46619 (9,11-dideoxy-9, 11-
methanoepoxy-prosta-5Z,13E-dien-1-oic acid) and ∆17-U-46619 (9,11-dideoxy-9, 
11-methanoepoxy-prosta-5Z,13E,17Z-trien-1-oic acid) (Cayman Chemical, Ann 
Arbor, MI, U.S.A.). All other reagents were of the highest grade available (Nacalai 
Tesque, Kyoto, Japan).
93.  Results
3.1.  Effects of centrally administered prostaglandin E2 and prostaglandin E3 on the 
plasma levels of catecholamines 
Blood sampling for 5 times during 60 min had no effect on the basal plasma 
levels of either noradrenaline or adrenaline (Fig. 1A and B). Treatment with vehicle 
(10 µl of 0.5% ethanol in saline, i.c.v.) also had no effect on the basal plasma levels of 
catecholamines (Fig. 1A and B). In preliminary studies, we monitored systemic blood 
pressure in our animal model since a large increase in peripheral noradrenaline is well 
known to alter systemic blood pressure. The blood pressure was largely unaffected by 
the blood sampling (data not shown). Ten minutes after administration of 
prostaglandin E2 (0.3 nmol/animal, i.c.v.), mean arterial blood pressure was increased 
from 76±6 to 106±10 mmHg (n=4).
Prostaglandin E2 [0.15, 0.3 and 1.5 nmol (53, 106 and 529 ng)/animal, i.c.v.] 
dose-dependently elevated the plasma level of noradrenaline (Fig. 1A). The responses
in each dose of prostaglandin E2 reached a maximum 10 min after administration of 
the reagent and then declined towards their basal levels (Fig. 1A). On the other hand, 
prostaglandin E2 (0.15, 0.3 and 1.5 nmol/animal, i.c.v.) slightly, but not significantly, 
elevated the plasma level of adrenaline (Fig. 1A).
I.c.v. administered prostaglandin E3 [0.3 nmol (105 ng)/animal] had little effect 
on the plasma level of noradrenaline, but a large dose of the reagent [3 nmol (1.1 
µg)/animal, i.c.v.] significantly elevated the plasma level of noradrenaline (Fig. 1B). 
The response also reached a maximum 10 min after administration of the reagent and 
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then declined toward the basal levels (Fig. 1B). On the other hand, prostaglandin E3
(0.3 and 3 nmol/animal, i.c.v.) slightly elevated the plasma level of adrenaline, but a 
maximal response was obtained by a dose of 0.3 nmol/animal (Fig. 1B).
3.2.  Effects of centrally administered U-46619 (an analog of thromboxane A2) and 
∆17-U-46619 (an analog of thromboxane A3) on the plasma levels of catecholamines
Treatment with vehicle (2.5 µl of DMF, i.c.v.) also had no effect on the basal 
plasma levels of catecholamines (Fig. 2A and B). U-46619 [30, 100 and 300 nmol (11, 
35 and 105 µg)/animal, i.c.v.] significantly elevated the plasma levels of noradrenaline
and adrenaline (adrenaline >> noradrenaline); maximal noradrenaline responses were 
obtained by a dose of 100 nmol/animal (i.c.v.) and maximal adrenaline responses were 
obtained by a dose of 300 nmol/animal (i.c.v.), respectively (Fig. 2A). The 
noradrenaline and adrenaline responses reached a maximum at 5 and 10 min after 
administration of U-46619, respectively, and then declined towards basal levels (Fig. 
2A).
I.c.v. administered ∆17-U-46619 [100 nmol (35 µg)/animal] had little effect on 
the plasma levels of noradrenaline and adrenaline, but the reagent significantly 
elevated the plasma levels of both catecholamines (adrenaline >> noradrenaline) with a 
large dose [300 nmol (105 µg)/animal, i.c.v.] (Fig. 2B). These responses reached a 
maximum 10 min after administration of the reagent and then declined towards basal 
levels (Fig. 2B).
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4.  Discussion
So far four types of prostanoid receptors (EP1, EP2, EP3 and EP4) have been 
identified to couple with prostaglandin E2 (Breyer et al., 2001). Prostanoid EP3
receptor mRNA is highly expressed in brain regions such as the hippocampus, preoptic 
area and hypothalamus (Sugimoto et al., 1994; Vasilache et al., 2007). Previously, we 
reported the involvement of brain prostanoid EP3 receptors in the centrally 
administered prostaglandin E2-induced elevation of plasma noradrenaline in rats 
(Yokotani et al., 1995). Recently, prostanoid EP3 receptors have been shown to bind
with less affinity and lower efficiency to prostaglandin E3 than prostaglandin E2 (Wada 
et al., 2007). In the present experiment, centrally administered prostaglandin E2 (0.15, 
0.3 and 1.5 nmol/animal) effectively elevated plasma noradrenaline in a dose-
dependent manner, while prostaglandin E3 effectively elevated plasma noradrenaline 
only at a larger dose (3 nmol/animal). Both prostaglandin E2 and E3 had little effect on
plasma adrenaline. These results suggest that centrally administered prostaglandin E3 is 
less effective than prostaglandin E2 to elevate plasma noradrenaline in rats. 
Messenger RNA of thromboxane receptors (prostanoid TP receptors) has been 
reported to be present in the brain (Namba et al., 1992; Gao et al., 1997). Previously, 
we reported that centrally administered thromboxane A2 mimetic induced the elevation 
of plasma catecholamines (adrenaline >> noradrenaline) by activation of the brain 
prostanoid TP receptors in rats (Murakami et al., 2002). In the present experiment, we 
used two analogs of thromboxane A2 and A3, U-46619 and ∆17-U-46619 (Abramovitz 
et al., 2000), because of the instability of thromboxanes (t1/2 for thromboxane A2, ~30 
s). Centrally administered U-46619 (100 and 300 nmol/animal) effectively elevated 
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plasma levels of both catecholamines (adrenaline >> noradrenaline) in rats. On the 
other hand, centrally administered ∆17-U-46619 significantly elevated plasma levels of 
both catecholamines (adrenaline >> noradrenaline) only at a larger dose (300 
nmol/animal), at this dose ∆17-U-46619-induced responses were almost the same as 
those induced by U-46619. Recently, it has been shown that both U-46619 and ∆17-U-
46619 activate human platelet aggregation via TP receptors and the EC50 values for 
them are similar (650 and 850 nM, respectively) (Wada et al., 2007). These lines of 
evidence suggest that centrally administered thromboxane A3 is almost equipotent for 
thromboxane A2 to elevate plasma catecholamines in rats.
Dietary supplements of fish oils rich in -3 PUFA have been reported to increase 
the levels of -3 PUFA (docosahexaenoic acid) in the hippocampus and forebrain of 
aged rats (Puskás et al., 2003; Dyall et al., 2007). Interestingly, these supplements have 
been shown to drastically reduce the levels of arachidonic acid in the hippocampus 
(Puskás et al., 2003). Recently, we reported the possibility that brain 
phosphatidylinositol-derived arachidonic acid is involved in the centrally administered 
histamine-induced elevation of plasma catecholamines (Shimizu et al., 2007). Dietary
-3 PUFA has been shown to increase the incorporation of -3 PUFA
(docosahexaenoic acid) in the brain structural phosphatidylinositol and to reduce blood 
pressure in hypertensive rats (de Wilde et al., 2003). These observations suggest a 
possibility that supplemented -3 PUFA competes with arachidonic acid at the level of 
incorporation into membrane phospholipids and at the level of substrate for 
cyclooxygenase, thereby increasing the synthesis of -3 prostanoids in the brain. 
Additionally, it has been reported that sympathetic outflow is reduced by -3 PUFA as 
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suggested by decreased plasma level of noradrenaline after increased dietary intake of 
fish or fish oils in humans or rats, respectively (Singer et al., 1983; Hashimoto et al., 
1999). Taken together with the results of the present study, -3 PUFA supplementation 
may attenuate the activation of central sympatho-adrenomedullary outflow by 
increasing the synthesis of -3 prostanoids such as prostaglandin E3 in the brain.
In summary, we demonstrated here that (1) centrally administered prostaglandin
E3 is less effective than prostaglandin E2 on elevation of plasma noradrenaline, and (2) 
centrally administered thromboxane A3 is almost as effective as thromboxane A2 on 
elevation of plasma catecholamines (adrenaline >> adrenaline) in rats.
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Legends to figures
Fig. 1. Effects of centrally administered prostaglandin E2 and prostaglandin E3 on the 
plasma levels of catecholamines. ∆Noradrenaline and ∆Adrenaline: increments of 
noradrenaline and adrenaline above the basal level. Each point represents the 
mean±S.E.M. (A) Arrow indicates the administration of vehicle (0.5% ethanol in saline
10 µl/animal, i.c.v.) or prostaglandin E2 (0.15, 0.3 and 1.5 nmol/animal, i.c.v.). 
*Significantly different from the vehicle-treated group with the Bonferroni method
[noradrenaline; at 5 min, F(3,19)=13.12, P<0.017; at 10 min, F(3,19)=26.39, P<0.017;
at 30 min, F(3,16)=5.09, P<0.017; at 60 min, F(3,19)=3.48, P<0.017]. (B) Arrow 
indicates the administration of vehicle or prostaglandin E3 (0.3 and 3 nmol/animal, 
i.c.v.). The vehicle-treated group is the same as that in (A). *Significantly different from 
the vehicle-treated group with the Bonferroni method [noradrenaline; at 5 min, 
F(2,14)=3.38, P<0.025; at 10 min, F(2,15)=6.43, P<0.025; at 30 min, F(2,15)=10.77, 
P<0.025; at 60 min, F(2,14)=8.02, P<0.025: adrenaline; at 5 min, F(2,15)=5.17, 
P<0.025; at 10 min, F(2,15)=5.27, P<0.025]. The actual values for noradrenaline and 
adrenaline at 0 min were 261±18 and 288±27 pg/ml (n=36), respectively.
Fig. 2. Effects of centrally administered U-46619 (an analog of thromboxane A2) and 
∆17-U-46619 (an analog of thromboxane A3) on the plasma levels of catecholamines.
Each point represents the mean±S.E.M. Other conditions are the same as those of Fig. 1.
(A) Arrow indicates the administration of vehicle (100% DMF 2.5 µl/animal, i.c.v.) or 
U-46619 (30, 100 and 300 nmol/animal, i.c.v.). *Significantly different from the 
vehicle-treated group with the Bonferroni method [noradrenaline; at 5 min, 
21
F(3,12)=7.20, P<0.017; at 10 min, F(3,12)=5.04, P<0.017: adrenaline; at 5 min, 
F(3,12)=8.67, P<0.017; at 10 min, F(3,12)=9.88, P<0.017; at 30 min, F(3,12)=10.41, 
P<0.017]. (B) Arrow indicates the administration of vehicle or ∆17-U-46619 (100 and 
300 nmol/animal, i.c.v.). The vehicle-treated group is the same as that in (A).
*Significantly different from the vehicle-treated group with the Bonferroni method
[noradrenaline; at 10 min, F(2,10)=7.31, P<0.025: adrenaline; at 10 min, F(2,10)=6.43, 
P<0.025; at 30 min, F(2,10)=14.17, P<0.025]. The actual values for noradrenaline and 
adrenaline at 0 min were 263±21 and 231±29 pg/ml (n=25), respectively.
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